Actelion Pharmaceuticals’ Opsumit (macitentan) may be a potential therapy for portopulmonary hypertension, according to positive results from a Phase 4…
Articles by Marta Figueiredo, PhD
Pulmonary arterial hypertension (PAH) affects the health of the gut’s microbial community, or microbiota, with an imbalance possibly being a factor…
Scleroderma patients diagnosed with pulmonary arterial hypertension (PAH) are at a high risk of PAH-related death, especially in the four years…
Direct oral anticoagulants — a type of blood thinner medication — are a safe and effective treatment for chronic thromboembolic…
Low levels of oxygen in the blood of people with idiopathic or heritable pulmonary arterial hypertension (IPAH or HPAH) are…
A single-dose of Ventavis (inhaled iloprost) is safe and effective in treating pulmonary hypertension (PH) associated with chronic…
A retrospective study showed that pulmonary arterial hypertension (PAH)-specific drug therapies do not raise the risk of respiratory tract infections…
A retrospective study found that patients with chronic thromboembolic pulmonary hypertension (CTEPH) have more pronounced decreases in mental health than those with …
The Pulmonary Hypertension Association of Canada has launched its Life in Purple Challenge campaign to mark November, Pulmonary Hypertension Awareness…
PhaseBio Pharmaceuticals has enrolled and dosed its first patient with pulmonary arterial hypertension (PAH) in a Phase 1 clinical…